Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.
Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, O'Brien TR; HALT-C Trial Group. Welzel TM, et al. Among authors: wright ec. Hepatology. 2009 Jun;49(6):1847-58. doi: 10.1002/hep.22877. Hepatology. 2009. PMID: 19434718 Free PMC article.
Corticosteroid therapy for chronic active hepatitis.
Berk PD, Jones EA, Plotz PH, Seeff LB, Wright EC. Berk PD, et al. Among authors: wright ec. Ann Intern Med. 1976 Oct;85(4):523-5. doi: 10.7326/0003-4819-85-4-523. Ann Intern Med. 1976. PMID: 788587 Clinical Trial. No abstract available.
Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study.
Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, Ishak KG, Iber FL, Toro D, Samanta A, Koretz RL, Perrillo RP, Goodman ZD, Knodell RG, Gitnick G, Morgan TR, Schiff ER, Lasky S, Stevens C, Vlahcevic RZ, Weinshel E, Tanwandee T, Lin HJ, Barbosa L. Seeff LB, et al. Among authors: wright ec. Hepatology. 2001 Feb;33(2):455-63. doi: 10.1053/jhep.2001.21905. Hepatology. 2001. PMID: 11172349
Use of complementary and alternative medicine in patients with liver disease.
Strader DB, Bacon BR, Lindsay KL, La Brecque DR, Morgan T, Wright EC, Allen J, Khokar MF, Hoofnagle JH, Seeff LB. Strader DB, et al. Among authors: wright ec. Am J Gastroenterol. 2002 Sep;97(9):2391-7. doi: 10.1111/j.1572-0241.2002.05993.x. Am J Gastroenterol. 2002. PMID: 12358262
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE; Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group. Shiffman ML, et al. Among authors: wright ec. Gastroenterology. 2004 Apr;126(4):1015-23; discussion 947. doi: 10.1053/j.gastro.2004.01.014. Gastroenterology. 2004. PMID: 15057741 Clinical Trial.
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.
Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright EC, Everhart JE; HALT-C Trial Group. Lee WM, et al. Among authors: wright ec. Control Clin Trials. 2004 Oct;25(5):472-92. doi: 10.1016/j.cct.2004.08.003. Control Clin Trials. 2004. PMID: 15465617 Clinical Trial.
208 results